What is Illumina’s (ILMN) Economic Moat, and is it Widening or Narrowing?

Illumina, Inc. (NASDAQ:ILMN) traded at around $268 on October 7, down 2.11% on the day, though still 183.61% higher over twelve months.

Revenue grew 9.40% in the most recent quarter while earnings fell 11.90%. A business selling more and earning less is the clearest sign a moat is being tested.

READ ALSO: What is eBay’s (EBAY) Economic Moat, and is it Widening or Narrowing?

The Moat Is the Consumable, Not the Machine:

Illumina sells sequencers, and the sequencers are not where the money is. A laboratory that installs one commits to buying Illumina reagents and flow cells for as long as the instrument runs. Switching means replacing capital equipment, retraining staff, and revalidating every assay built on the old platform.

That is why a 67.93% gross margin has survived in an industry that competes on price per genome. Return on equity of 32.34% shows the installed base still earning well above the cost of the capital inside it.

Operating margin of 21.14% shows how much of that gross margin survives the research spending the platform requires. Free cash flow of $931.00 million against $824.00 million of net income confirms the reagent revenue is collected rather than booked. In January we ranked ten stocks for high returns. The one we put first has returned almost 30% since.

What the Earnings Line Is Telling You:

Revenue grew 9.40%, and earnings fell 11.90%. Growing the top line while losing profit is consistent with the price per run falling faster than volume rises. That is what a narrowing moat looks like on an income statement, because the consumables are no longer priced at will.

The market has priced the slowdown rather than the margin. A forward multiple of 43.83 sits barely below the trailing 49.96. A PEG ratio of 3.38 says the growth on offer does not support the multiple on any reasonable arithmetic. Net margin of 18.34% is still a healthy figure, so the pressure is on the direction of travel rather than on the level.

Short interest of 11.47% of the float is a large position against a company whose shares have risen 183.61%. In May, we ranked this year’s best dividend performers. The one that finished first has since fallen 38%.

The Valuation Case:

Illumina traded at around $268 on October 7 and is worth $40.43 billion. Sustainability depends on sequencing volumes rather than on instrument sales, which is the whole logic of the razor and blade model. On price, the stock sits at 49.96 times trailing earnings and 9.00 times sales. A price-to-book of 14.25 against a book value of $18.80 a share says almost none of this value is in the physical assets. Debt-to-equity of 89.04% on $2.53 billion of borrowings is manageable against $1.17 billion of cash.

Conclusion:

The moat is wide and no longer pricing freely. Switching costs built into every validated assay still deliver a 67.93% gross margin and a 32.34% return on equity, and $931.00 million of free cash flow exceeds reported net income. However, revenue grew 9.40% while earnings fell 11.90%, so the extra volume is not reaching the bottom line. A PEG ratio of 3.38 and a forward multiple of 43.83 leave no room for that to continue. The number to watch is gross margin, because 67.93% is the figure the entire installed base exists to defend.

Market Sentiment:

Illumina, Inc. was held by 54 hedge funds with a combined stake value of about $3.02 billion at the end of Q2 2026 in the Insider Monkey database. This is up from 48 hedge fund holders with a cumulative investment value of around $3.04 billion in the previous quarter.

READ NEXT: Here is Why Tripadvisor (TRIP) is a Bad Investment at Today’s Price and What is eBay’s (EBAY) Economic Moat, and is it Widening or Narrowing?

This article is originally published at Insider Monkey.